Predicting optimal deep brain stimulation parameters for Parkinson's disease using functional MRI and machine learning
- PMID: 34031407
- PMCID: PMC8144408
- DOI: 10.1038/s41467-021-23311-9
Predicting optimal deep brain stimulation parameters for Parkinson's disease using functional MRI and machine learning
Abstract
Commonly used for Parkinson's disease (PD), deep brain stimulation (DBS) produces marked clinical benefits when optimized. However, assessing the large number of possible stimulation settings (i.e., programming) requires numerous clinic visits. Here, we examine whether functional magnetic resonance imaging (fMRI) can be used to predict optimal stimulation settings for individual patients. We analyze 3 T fMRI data prospectively acquired as part of an observational trial in 67 PD patients using optimal and non-optimal stimulation settings. Clinically optimal stimulation produces a characteristic fMRI brain response pattern marked by preferential engagement of the motor circuit. Then, we build a machine learning model predicting optimal vs. non-optimal settings using the fMRI patterns of 39 PD patients with a priori clinically optimized DBS (88% accuracy). The model predicts optimal stimulation settings in unseen datasets: a priori clinically optimized and stimulation-naïve PD patients. We propose that fMRI brain responses to DBS stimulation in PD patients could represent an objective biomarker of clinical response. Upon further validation with additional studies, these findings may open the door to functional imaging-assisted DBS programming.
Conflict of interest statement
R.M., S.E.J. and J.A. are employees at General Electric. B.L. is now a Medtronic employee; he was not at the time of this work completion. Medtronic had no role in data acquisition, analysis, or interpretation. A.F. serves as a consultant for Medtronic, Abbott, Boston Scientific, Brainlab, Ceregate, and Medtronic, he received research grants, personal fees and non-financial support from Boston Scientific, Brainlab and Medtronic and personal fees from Abbott and Ceregate, all outside the submitted work. S.K.K. reports honorarium and consulting fees from Medtronic. A.M.L. serves as a consultant for Medtronic, Abbott, Boston Scientific, and Functional Neuromodulation. A.B., R.M., S.E.J., J.A. and A.M.L. have intellectual property related to this manuscript. The other authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Figures





Comment in
-
Novel biomarkers and neuroimaging techniques in Parkinson's disease.J Neurol. 2024 Feb;271(2):1056-1058. doi: 10.1007/s00415-024-12187-6. Epub 2024 Jan 17. J Neurol. 2024. PMID: 38231269 Free PMC article. No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical